Keep the evidence and operating model current. Suggested cadence: weekly operational review during stabilisation, monthly cost and fulfilment reconciliation, and event-triggered review when a product, facility, state, programme term or legal position changes.
Assign owners for licence monitoring, quality notices, programme eligibility, price changes, contract notices and patient communications. Refresh the approved-route record before adding a new state or material product arrangement.
Recent developments illustrate the need for clinical ownership of updates: FDA issued a GLP-1 safety communication on November 9, 2026 requiring labelling changes concerning a potential increased risk of a serious eye condition. Clinical leadership—not procurement—should determine the implications for prescribing information, education and escalation materials. (fda.gov)
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential